Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary Safety and PK of CVT-427 in Smokers and Asthmatics
NCT02905227Phase 1Completed
- Sponsor
- Acorda Therapeutics
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zolmitriptan in migraine (3 arms), sponsored by Acorda Therapeutics. Primary endpoints: Change in measure of pulmonary function via Spirometry at 24 hours, Maximum observed plasma drug concentration at 24 hours and 2 more. Started Sep 2016; status: completed.
02
Drugs
zolmitriptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02905227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905227.